Therapy Areas: Vaccines
Preliminary data suggests AstraZeneca COVID-19 booster generates higher antibodies against Omicron variant
13 January 2022 -

British pharmaceutical company AstraZeneca plc (LON:AZN) has said that preliminary data from a trial conducted on its COVID-19 vaccine Vaxzevria showed it generated a higher antibody response against the Omicron variant and others, including Beta, Delta, Alpha and Gamma, when given as a third booster dose, Reuters news agency reported on Thursday.

According to the company, this increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine.

AstraZeneca added that it would submit this data to regulators worldwide given the urgent need for boosters.

Lab studies last month found that a three-dose course of Vaxzevria was effective against the rapidly spreading Omicron variant.